" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cell Medica Opens Commercial Manufacturing Facility in Germany

Published: Thursday, September 26, 2013
Last Updated: Thursday, September 26, 2013
Bookmark and Share
Commercial launch of Cytovir CMV is planned for early 2014.

Imperial Innovations Group plc has announced that portfolio company Cell Medica has opened a European manufacturing facility in Berlin-Buch, Germany.

T cell immunotherapy involves harnessing the human immune system to treat diseases and Cell Medica is using the approach to develop, manufacture and market treatments of infections and cancers related to oncogenic (cancer-causing) viruses.

Cell Medica’s commercial manufacturing facility at the Max-Delbrück-Center of Molecular Medicine within the biotechnology area of Campus Berlin-Buch includes approximately 350 m2 clean room space, and will initially focus on manufacturing the company’s Cytovir™ CMV.

The innovative Cytovir CMV treatment uses immune cells of a healthy donor to restore immunity to Cytomegalovirus infections in patients who have lost their immunity following a bone marrow transplant.

The commercial launch of Cytovir CMV is planned for early 2014, following the completion of two randomized controlled studies currently ongoing in the UK.

The financing of Cell Medica’s investment in the Berlin-Buch facility is supported in part by the Investitionsbank Berlin (IBB), the business development and promotion bank of the Federal Land of Berlin.

The facility will also be important in providing investigational medicine products for Cell Medica’s planned CITADEL study to investigate a T cell therapy for the treatment of EBV-associated lymphomas, which will be undertaken following the required regulatory approvals.

Cell Medica is one of Innovations’ leading portfolio companies and represents the strength in depth of the Group’s top ten assets. In July 2012, Innovations committed £3 million as part of a £17 million funding round for Cell Medica. Innovations holds a 30% stake in the business.

Russ Cummings, Chief Executive Officer, Imperial Innovations, said: “The opening of a European manufacturing facility is a significant step towards Cell Medica bringing its lead product, Cytovir CMV, to market. We have been able to scale-up our investment over time to help Cell Medica’s excellent team maintain its industry-leading position and grow the value of the company.”

Dr Rainer Knaus, Managing Director of Cell Medica GmbH, said: “This facility has been designed and equipped to provide high quality Good Manufacturing Practice (GMP) compliant production of patient-specific cell and gene therapies for distribution across Europe. We are also very fortunate to have attracted highly educated and well-trained personnel who are keen to help shape this new era of cell-based therapeutics. These manufacturing specialists are preparing the facility for the supply of Cytovir CMV in early 2014.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Innovations Leads £3 Million Investment in Abingdon Health
Company has appointed Chris Yates as CEO.
Tuesday, July 07, 2015
Cell Medica Announces Start of Commercial Cell Therapy Manufacture
Manufacturing will be focused on Cytovir™ CMV for the treatment of patients with CMV infections.
Friday, February 20, 2015
Imperial Innovations Leads £18 Million Series B Funding Round in Veryan
Innovations will hold a 47.8% stake in the issued share capital of Veryan.
Saturday, January 17, 2015
MISSION Therapeutics Receives £20m Series B Funding
Financing round will enable MISSION to advance its programmes for the treatment of cancers.
Monday, December 09, 2013
Circassia’s Grass Allergy Treatment Achieves Significant Symptom Reduction
Circassia has achieved successful results from a large phase II clinical study of its grass allergy treatment.
Tuesday, October 08, 2013
Veryan Receives CE Mark Approval for BioMimics 3D™ Stent
A novel platform technology designed for treating the major arteries of the leg in patients with PAD.
Monday, November 19, 2012
Innovations Invests in £17 Million Funding Round for Portfolio Company, Cell Medica
Cell Medica continue to develop immune reconstitution cell therapies in Europe and to launch new operations in US.
Tuesday, July 24, 2012
Innovations Leads £3m Funding Round in Abingdon Health
Company invests £2m in this round.
Tuesday, March 27, 2012
Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!